{"id":"NCT00650078","sponsor":"Amgen","briefTitle":"Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis","officialTitle":"A Randomized Multi-Center, Double-Blind, Placebo-Controlled Study of a New Modified-Release Tablet Formulation of Prednisone (Lodotra®) in Patients With Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2009-05","completion":"2009-05","firstPosted":"2008-04-01","resultsPosted":"2012-12-13","lastUpdate":"2024-12-18"},"enrollment":350,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"MR prednisone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"NP01","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to compare the safety and efficacy, with regards to the signs and symptoms, of MR prednisone (Lodotra®) versus placebo in combination with standard Disease Modifying Anti-Rheumatic Drug (DMARD) treatment in patients with active rheumatoid arthritis.","primaryOutcome":{"measure":"ACR 20 Response Rate at Visit 4","timeFrame":"Week 12","effectByArm":[{"arm":"NP01","deltaMin":108,"sd":null},{"arm":"Placebo","deltaMin":34,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0010"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":52,"countries":["United States","Canada","Germany","Hungary","Poland","United Kingdom"]},"refs":{"pmids":["26535146","22562974"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":231},"commonTop":["arthralgia","rheumatoid arthritis","nasopharyngitis","headache","bronchitis"]}}